THE ROLE OF ANTIBODIES IN GYNECOLOGICAL TUMORS
Keywords:
Key words: gynecological tumors, antibodies, monoclonal antibodies, antibody-drug conjugates, ovarian cancer, cervical cancer, immunotherapy, tumor markers, targeted therapyAbstract
Annotation: During the last decades, several improvements in treating
gynecological malignancies have been achieved. In particular, target therapies, mostly
monoclonal antibodies, have emerged as an attractive option for the treatment of these
malignancies. In fact, various molecular-targeted agents have been developed for a
variety of malignancies with the objective to interfere with a precise tumor associated
receptor, essential for cancer cell survival or proliferation, blocking its function, of the
cancer cells. This article examines the role of antibodies in the diagnosis, treatment,
and monitoring of gynecological tumors, including ovarian, cervical, and endometrial
cancers. It highlights how monoclonal antibodies and antibody-based therapies, such
as antibody-drug conjugates and immune checkpoint inhibitors, are being used to target
tumor-specific antigens.
References
References:
1. Markman, M. (2019). Monoclonal antibodies in the management of ovarian
cancer: Current status and future prospects. Cancer, 125(13), 2115–
2123. https://doi.org/10.1002/cncr.32034
2. Cohen, P. A., Jhingran, A., Oaknin, A., & Denny, L. (2019). Cervical cancer.
The Lancet, 393(10167), 169–182. https://doi.org/10.1016/S0140-
6736(18)32470-X
3. Tanyi, J. L., & Scholler, N. (2020). Monoclonal antibody-based therapies for
gynecologic cancers: Current clinical uses and future promise. Current Opinion
in Obstetrics and Gynecology, 32(1), 28–
36. https://doi.org/10.1097/GCO.0000000000000600
4. Marth, C., Landoni, F., Mahner, S., McCormack, M., Gonzalez-Martin, A., &
Colombo, N. (2017). Cervical cancer: ESMO Clinical Practice Guidelines.
Annals of Oncology, 28(suppl_4), iv72–
iv83. https://doi.org/10.1093/annonc/mdx220
5. Zamarin, D., Burger, R. A., Sill, M. W., Powell, M. A., & Lankes, H. A.
(2020). Randomized Phase II Trial of Nivolumab in Combination With
Ipilimumab or Bevacizumab in Recurrent Ovarian Cancer. Journal of Clinical
Oncology, 38(16), 1814–1823.
